SAN DIEGO--(BUSINESS WIRE)--Critical Diagnostics, makers of the cardiac biomarker ST2, announced the election of Richard Dee to its Board of Directors.
Richard is a Board Director and Senior Vice President at Unilab in Manila, Philippines. He oversees Unilab's regional interests in biotechnology and most recently, diagnostics. Richard's career in Unilab spans over two decades and continues to be focused on ethical medicine business development. Richard graduated from the University of British Columbia in Vancouver as a Bachelor of Commerce. He completed his MBA at the Wharton School of the University of Pennsylvania. He concurrently sits on the boards of Assisi Development Foundation and ASA microfinance in the Philippines, and Temasek Lifescience Laboratories in Singapore.
“We are extremely pleased to have Richard join our Board of Directors,” comments Critical Diagnostics’ CEO and Founder, David Geliebter. “He brings years of valuable industry experience, insights and relationships to our organization, and at a critical juncture in our company’s history, as we continue to expand our business internationally and add new diagnostic products.”
Unilab is Critical Diagnostics’ distribution partner in the Philippines. Unilab is the leading Southeast Asian pharmaceutical-healthcare concern. It develops and markets a country-centric spectrum of products across the ASEAN region and China with a portfolio that includes some of the most trusted consumer healthcare brands in Asia.
Unilab's mission is "to provide quality and affordable healthcare products and services that promote and enrich life for all communities that we serve by working together as one United family."
“We are proud to be more closely associated with Unilab,” notes Geliebter. “That spirit of genuine concern for making the lives of people better that drives Unilab, is shared equally by Critical Diagnostics and rooted in everything we do.”
About ST2
ST2 is a soluble protein expressed by the heart in response to disease or injury. It is reflective of ventricular remodeling and cardiac fibrosis. Unlike many other cardiac biomarkers, ST2 levels change quickly in response to changes in the patient’s condition—thus helping physicians make informed decisions on an appropriate course of action to take and, if needed, to quickly adjust treatment. All this makes ST2 an ideal serial biomarker for monitoring and treating heart failure patients.
The Presage® ST2 Assay from Critical Diagnostics is the only commercially available ST2 biomarker in the world. The Presage ST2 Assay has been CE Marked and cleared by the U.S. FDA for use as an aid in the risk stratification of chronic heart failure patients.
The 2013 ACC/AHA Guideline for the Management of Heart Failure, recognizes ST2 as “not only predictive of hospitalization and death in patients with HF but also additive to natriuretic peptide levels in [its] prognostic value.”
About Critical Diagnostics
Founded in 2004, Critical Diagnostics (www.criticaldiagnostics.com) develops novel biomarkers to help physicians optimize patient care in cardiovascular diseases, while containing healthcare costs. Critical Diagnostics has distribution partners for its Presage ST2 Assay in 45 countries, covering two-thirds of the world’s population.
